Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  AUSTRALIAN SECURITIES EXCHANGE LIMITED  >  Cochlear Limited    COH   AU000000COH5

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Cochlear Limited : COH Jury Trial Verdict on USA Patent Infringement Case

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/24/2014 | 03:51am CEST
ASX RELEASE 24th January 2014 COCHLEAR LIMITED: JURY TRIAL VERDICT ON USA PATENT INFRINGEMENT CASE

Cochlear Limited, Sydney, 24th January 2014 (ASX:COH) today announced that a jury verdict in the patent infringement lawsuit by the Alfred E. Mann Foundation for Scientific Research ("AMF") and Advanced Bionics LLC ("AB") has been reached.
A jury in the United States District Court in Los Angeles, California found direct, contributory and wilful, but not induced infringement against Cochlear Limited and its USA subsidiary Cochlear Americas and awarded damages of US$131.2 million against Cochlear.
No judgment has been entered based on the verdict as important issues still remain to be decided by the Judge. These decisions may negate some of the findings of the jury and could alter the damages awarded by the jury.
Cochlear believes the facts and the law do not support the jury's findings and will seek to overturn the verdict in post-trial motions with the District Court and, if necessary, through the appeals process.
This lawsuit was disclosed to ASX when it was filed in December 2007. The verdict relates to two (2) United States patents on testing systems and methods for a cochlear implant. The patents were exclusively licenced by AMF to AB which is a competitor to Cochlear.
One of the patents expired in September 2009 and the other expires in March 2014. As a result, the verdict and any following judgment entered against Cochlear will not disrupt Cochlear's business or customers in the United States.
As at the date of this announcement, Cochlear had not accrued any liability in its financial statements for this verdict. In addition, Cochlear has not yet determined the impact, if any, on its financial statements.
Cochlear's Chief Executive Officer and President Dr Chris Roberts said, "We strongly disagree with the jury verdict and will appeal any judgment entered against Cochlear by the Court".
Ends
Company contacts:
Dr Chris Roberts, CEO/President p: + 61 2 9428 6555
Neville Mitchell, CFO
p: + 61 2 9428 6555

Page 1 of 1

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on COCHLEAR LIMITED
06/22 COCHLEAR : Becoming a substantial holder
06/08 COCHLEAR : celebrates the 40th anniversary of the world's first bone conduction ..
06/01 COCHLEAR : Patent Issued for Control for Hearing Prosthesis Fitting (USPTO 96560..
05/31 COCHLEAR LIMITED : Supports WHO Hearing Health Policy Action Plan
05/31 COCHLEAR : applauds WHO hearing health action plan for prevention of deafness an..
05/27 COCHLEAR : acquires exclusive licence to Artificial Intelligence assistant to su..
05/26 COCHLEAR : Partners with Otoconsult NV on FOX Fitting Assistant
05/11 COCHLEAR : Purchases Sycle
05/11 COCHLEAR : acquires audiology practice management software
05/07 COCHLEAR : Launches Million Ear Challenge
More news
Sector news : Medical Prosthetics
05/23DJFirms Persuade SEC on Profit Metric -- WSJ
05/22DJCompanies Are Winning the Battle Over Adjusted Earnings
05/16 Earnings drag on European shares, though Vodafone lifts telcos
05/09 French outbound M&A driven to decade high by big deals
05/06DJProfits Jump, Spending Lags -- WSJ
More sector news : Medical Prosthetics
News from SeekingAlpha
2016 How Do I Manage A Favorite Holding That's Now Overvalued?
2016 Smaller Medtechs In Charge Of Their Own Destiny
2016 The Psychology Of Investing
2016 EWA : Getting In Down Under
2015 Cochlear Should Do Well As Its Target Market Expands
Advertisement
Financials ( AUD)
Sales 2017 1 232 M
EBIT 2017 310 M
Net income 2017 222 M
Debt 2017 93,3 M
Yield 2017 1,70%
P/E ratio 2017 40,98
P/E ratio 2018 36,27
EV / Sales 2017 7,51x
EV / Sales 2018 6,76x
Capitalization 9 156 M
More Financials
Chart COCHLEAR LIMITED
Duration : Period :
Cochlear Limited Technical Analysis Chart | COH | AU000000COH5 | 4-Traders
Full-screen chart
Technical analysis trends COCHLEAR LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 133  AUD
Spread / Average Target -17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christopher M. Smith President, Chief Executive Officer & Director
Roderick Holliday-Smith Chairman
Dig Howitt Chief Operating Officer
Brent Cubis Chief Financial Officer
James F. Patrick Chief Scientist & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
COCHLEAR LIMITED30.10%6 701
SONOVA HOLDING32.90%11 044
STRAUMANN HOLDING41.26%9 120
INSULET CORPORATION29.51%2 777
MODERN DENTAL GROUP LT..7.27%397
REWALK ROBOTICS LTD-35.71%31
More Results